Login / Signup
Thomas M Estok
ORCID
Publication Activity (10 Years)
Years Active: 2022-2022
Publications (10 Years): 1
Top Topics
Flow Cytometry
Dendritic Cells
Gene Expression
Childhood Cancer
Top Venues
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Yumi Yokoyama
,
Thomas M Estok
,
Robert Wild
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Molecular cancer therapeutics
21 (10) (2022)